Not exact matches
These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in
revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger
than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay
dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future
revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).
If pre-product, pre-
revenue companies (i.e. loss making, just idea stage) can be valued for $ 10 — $ 20 million, why can't Financial Samurai, which is highly profitable, has six years of existence, can pay a nice
dividend if it wants to, has way less risk
than all these new startups, and can grow
revenue by triple digits every year with promotion, be worth a similar range?
Unilever posted better -
than - expected first quarter
revenues and increased its quarterly
dividend by 12 % as it continues to appease shareholders after a failed takeover attempt by Kraft Heinz.
MarketCap / GVA is better correlated with actual subsequent S&P 500 total returns
than price / forward earnings, the Fed Model, the Shiller P / E, price / book, price /
dividend, Tobin's Q, market capitalization to GDP, price /
revenue and every other valuation ratio we've developed or examined in market cycles across history.
More
than 90 percent of the
revenues were accounted for by
dividends and less
than 10 percent by interest payments.
With a stable and predictable
revenue stream (more
than 95 % of cash flows secured under long - term contract or similar arrangements), Enbridge expects to offer an attractive annual
dividend growth rate of 10 % through 2020.
UK stocks (as measured by the FTSE 100 Index) offer the highest
dividend yield of any major region (as measured by the MSCI World Index).1 UK valuations are the cheapest relative to the rest of the world in 15 years.2 What's more, FTSE 100 Index companies with more
than 70 % of their
revenues from abroad stand to benefit from the weaker pound.
The Internal
Revenue Service requires a Schedule B form in a number of situations, but for the average taxpayer, the two most common reasons are earning more
than $ 1,500 of interest or
dividend income (from savings accounts or stocks, for example) and to exclude the interest you earn on certain U.S. savings bonds from your tax return.
More
than 90 percent of the
revenues were accounted for by
dividends and less
than 10 percent by interest payments.
Preferreds offer an advantage over bonds in that their
dividends receive more favourable tax treatment from the Canada
Revenue Agency
than does interest income.
Most investors are craving for
revenue and
dividend stocks are pretty much the answer to this desire... unless they continue to starve with their bonds and CDs paying less interest
than I pay my kids!
But earnings per share and
dividend grew a lot faster
than revenues.
But rather
than lowering an existing tax, it relies on a so - called tax - and -
dividend model: As the state of Alaska does with oil
revenues,
revenues from the Council's national carbon tax would be returned equally to all American households in quarterly «
dividends» digitally deposited in Social Security accounts.
I am proposing something better
than that — Carbon Fee &
Dividend or what some might call a revenue - neutral tax meaning the fee income will be given back to the people equally in the form of a monthly dividen
Dividend or what some might call a
revenue - neutral tax meaning the fee income will be given back to the people equally in the form of a monthly
dividenddividend check.
Examined another way, the $ 874K TH granted under LEAP represented about a tenth of 1 % (1 / 10th) of their Gross
Revenues (net of Cost of Power), less
than 1 % of pre-tax profits and 2 % of
dividend payments to the City of Toronto for 2013.